<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353990</url>
  </required_header>
  <id_info>
    <org_study_id>2006-002803-15</org_study_id>
    <nct_id>NCT00353990</nct_id>
  </id_info>
  <brief_title>Bioavailability of Insulin Administered in Duodenum</brief_title>
  <official_title>Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart Administered in the Duodenum in Healthy Volunteers - an Open Single Blinded and Uncontrolled Explorative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the bioavailability of insulin after infusion in the duodenum in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHODOLOGY All subjects will be admitted fasting to the Clinical Trial Unit at Ã…rhus&#xD;
      Community Hospital at 8 a.m. A Gastrointestinal tube will be placed in Duodenum distal to&#xD;
      papilla Vaterii with a pH of approximately 7.0 as measured by the pH meter distal in the&#xD;
      tube. An indwelling catheter for glucose infusion (20 %) in cases of hypoglycaemia will be&#xD;
      placed in an antecubital vein. In the contralateral anticubital vein a catheter will be&#xD;
      placed for blood sampling. All subjects will have 4 tests with duodenal infusion of the&#xD;
      insulin Aspart solution. The first 4 volunteers will receive 4 doses of insulin Aspart&#xD;
      solution in 1 ml (150, 300, 600 and 1000 IU) with 3-6 hours apart. Blood sampling for Insulin&#xD;
      Aspart, total insulin, and glucose (Beckmann apparatus) will be done every 10 minutes the&#xD;
      first two hours, and then every 20 minutes. When final the subjects will receive a meal&#xD;
      before leaving the hospital.&#xD;
&#xD;
      Based on data from the pilot a dose will be determined for the remaining 8 subjects. These&#xD;
      will then based again on results from the pilot on two separate study days receive 4&#xD;
      infusions with 3-6 hours split. Two infusions will be at pH 7 and two infusions will be more&#xD;
      proximal at a pH of 5.5 (two different insulin concentrations but the same dose given at the&#xD;
      two places in Duodenum). Frequency and interval of blood sampling in the second part will be&#xD;
      determined by results from the pilot study. For comparison with the clinical situation and&#xD;
      estimation of bioavailability all subjects will receive a subcutaneous and an intravenous&#xD;
      (iv) bolus injection of 6 IU of insulin Aspart. The iv injection will be followed by blood&#xD;
      sampling for three hours as above, but every 5 minutes the first two hours, and the sc&#xD;
      injection will be followed by blood sampling for three hours as above, but again with 10&#xD;
      minutes interval the first two hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the bioavailability of a solution of insulin Aspart infused in the Duodenum</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetics of insulin following duodenal administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate intra- and intersubjects variation in pharmacokinetic</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacodynamics of insulin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess any safety issues</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore any influence of PH/ insulin concentration on PK /PD parameters</measure>
  </secondary_outcome>
  <enrollment>12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Healthy Volunteers&#xD;
&#xD;
          -  Age &gt;18 - &lt; 50 years&#xD;
&#xD;
          -  BMI 18-30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of gastrointestinal or endocrine disorders (e.g. diabetes mellitus)&#xD;
&#xD;
          -  pregnancy or nursing&#xD;
&#xD;
          -  suspected or known allergy towards the drug&#xD;
&#xD;
          -  Participation in other research trials within 3 months before the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torben Laursen, MD, DMSc, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Aarhus Sygehus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte A Ihlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinilogy, Universityhospital of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Department M</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2006</study_first_posted>
  <last_update_submitted>April 24, 2007</last_update_submitted>
  <last_update_submitted_qc>April 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2007</last_update_posted>
  <keyword>insulin</keyword>
  <keyword>bioavailability</keyword>
  <keyword>duodenum</keyword>
  <keyword>infusion</keyword>
  <keyword>healthy</keyword>
  <keyword>diabetes</keyword>
  <keyword>absorption</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

